Literature DB >> 23423977

Automated tracking of nanoparticle-labeled melanoma cells improves the predictive power of a brain metastasis model.

Terje Sundstrøm1, Inderjit Daphu, Ingvild Wendelbo, Erlend Hodneland, Arvid Lundervold, Heike Immervoll, Kai Ove Skaftnesmo, Michal Babic, Pavla Jendelova, Eva Sykova, Morten Lund-Johansen, Rolf Bjerkvig, Frits Thorsen.   

Abstract

Biologic and therapeutic advances in melanoma brain metastasis are hampered by the paucity of reproducible and predictive animal models. In this work, we developed a robust model of brain metastasis that empowers quantitative tracking of cellular dissemination and tumor progression. Human melanoma cells labeled with superparamagnetic iron oxide nanoparticles (SPION) were injected into the left cardiac ventricle of mice and visualized by MRI. We showed that SPION exposure did not affect viability, growth, or migration in multiple cell lines across several in vitro assays. Moreover, labeling did not impose changes in cell-cycle distribution or apoptosis. In vivo, several SPION-positive cell lines displayed similar cerebral imaging and histologic features. MRI-based automated quantification of labeled cells in the brain showed a sigmoid association between metastasis frequency and doses of inoculated cells. Validation of this fully automated quantification showed a strong correlation with manual signal registration (r(2) = 0.921, P < 0.001) and incidence of brain metastases (r(2) = 0.708, P < 0.001). Metastasis formation resembled the pattern seen in humans and was unaffected by SPION labeling (histology; tumor count, P = 0.686; survival, P = 0.547). In summary, we present here a highly reproducible animal model that can improve the predictive value of mechanistic and therapeutic studies of melanoma brain metastasis. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23423977     DOI: 10.1158/0008-5472.CAN-12-3514

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

Review 1.  A physiological perspective on the use of imaging to assess the in vivo delivery of therapeutics.

Authors:  Shengping Qin; Brett Z Fite; M Karen J Gagnon; Jai W Seo; Fitz-Roy Curry; Frits Thorsen; Katherine W Ferrara
Journal:  Ann Biomed Eng       Date:  2013-09-10       Impact factor: 3.934

2.  Melanoma brain metastasis is independent of lactate dehydrogenase A expression.

Authors:  Terje Sundstrøm; Heidi Espedal; Patrick N Harter; Kristine Eldevik Fasmer; Kai Ove Skaftnesmo; Sindre Horn; Erlend Hodneland; Michel Mittelbronn; Benjamin Weide; Rudi Beschorner; Benjamin Bender; Cecilie Brekke Rygh; Morten Lund-Johansen; Rolf Bjerkvig; Frits Thorsen
Journal:  Neuro Oncol       Date:  2015-03-19       Impact factor: 12.300

Review 3.  In vivo animal models for studying brain metastasis: value and limitations.

Authors:  Inderjit Daphu; Terje Sundstrøm; Sindre Horn; Peter C Huszthy; Simone P Niclou; Per Ø Sakariassen; Heike Immervoll; Hrvoje Miletic; Rolf Bjerkvig; Frits Thorsen
Journal:  Clin Exp Metastasis       Date:  2013-01-16       Impact factor: 5.150

Review 4.  Brain metastases in non-small-cell lung cancer: better outcomes through current therapies and utilization of molecularly targeted approaches.

Authors:  Rimas V Lukas; Maciej S Lesniak; Ravi Salgia
Journal:  CNS Oncol       Date:  2014-01

Review 5.  Melanoma central nervous system metastases: current approaches, challenges, and opportunities.

Authors:  Justine V Cohen; Hussain Tawbi; Kim A Margolin; Ravi Amravadi; Marcus Bosenberg; Priscilla K Brastianos; Veronica L Chiang; John de Groot; Isabella C Glitza; Meenhard Herlyn; Sheri L Holmen; Lucia B Jilaveanu; Andrew Lassman; Stergios Moschos; Michael A Postow; Reena Thomas; John A Tsiouris; Patrick Wen; Richard M White; Timothy Turnham; Michael A Davies; Harriet M Kluger
Journal:  Pigment Cell Melanoma Res       Date:  2016-10-22       Impact factor: 4.693

6.  Trifluoperazine prolongs the survival of experimental brain metastases by STAT3-dependent lysosomal membrane permeabilization.

Authors:  Xin Zhang; Kaikai Ding; Jianxiong Ji; Himalaya Parajuli; Synnøve Nymark Aasen; Heidi Espedal; Bin Huang; Anjing Chen; Jian Wang; Xingang Li; Frits Thorsen
Journal:  Am J Cancer Res       Date:  2020-02-01       Impact factor: 6.166

7.  Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome.

Authors:  Diego M Marzese; Michelle Liu; Jamie L Huynh; Hajime Hirose; Nicholas C Donovan; Kelly T Huynh; Eiji Kiyohara; Kelly Chong; David Cheng; Ryo Tanaka; Jinhua Wang; Donald L Morton; Garni Barkhoudarian; Daniel F Kelly; Dave S B Hoon
Journal:  Pigment Cell Melanoma Res       Date:  2014-09-30       Impact factor: 4.693

8.  Multimodal imaging enables early detection and characterization of changes in tumor permeability of brain metastases.

Authors:  Frits Thorsen; Brett Fite; Lisa M Mahakian; Jai W Seo; Shengping Qin; Victoria Harrison; Sarah Johnson; Elizabeth Ingham; Charles Caskey; Terje Sundstrøm; Thomas J Meade; Patrick N Harter; Kai Ove Skaftnesmo; Katherine W Ferrara
Journal:  J Control Release       Date:  2013-10-29       Impact factor: 9.776

Review 9.  The use of molecular imaging combined with genomic techniques to understand the heterogeneity in cancer metastasis.

Authors:  R Chowdhury; B Ganeshan; S Irshad; K Lawler; M Eisenblätter; H Milewicz; M Rodriguez-Justo; K Miles; P Ellis; A Groves; S Punwani; T Ng
Journal:  Br J Radiol       Date:  2014-03-06       Impact factor: 3.039

Review 10.  Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines.

Authors:  Manuel Valiente; Amanda E D Van Swearingen; Carey K Anders; Amos Bairoch; Adrienne Boire; Paula D Bos; Diana M Cittelly; Neta Erez; Gino B Ferraro; Dai Fukumura; Brunilde Gril; Meenhard Herlyn; Sheri L Holmen; Rakesh K Jain; Johanna A Joyce; Mihaela Lorger; Joan Massague; Josh Neman; Nicola R Sibson; Patricia S Steeg; Frits Thorsen; Leonie S Young; Damir Varešlija; Adina Vultur; Frances Weis-Garcia; Frank Winkler
Journal:  Cancer Res       Date:  2020-07-08       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.